Novel sequence variants and common recurrent polymorphisms of BRCA2 in Sri Lankan breast cancer patients and a family with BRCA1 mutations

SUMADEE DE SILVA1, KAMANI H. TENNEKOON1, ERIC H. KARUNANAYAKE1, WASANTHI DE SILVA1, INDRANI AMARASINGHE2 and PREETHIKA ANGUNAWELA3

1Institute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo, Colombo 03; 2National Cancer Institute, Maharagama; 3Department of Pathology, Faculty of Medicine, University of Colombo, Colombo 08, Sri Lanka

Received June 28, 2011; Accepted August 2, 2011

DOI: 10.3892/etm.2011.337

Abstract. We previously reported BRCA1 mutations and sequence variants in Sri Lankan breast cancer patients. Mutations and sequence variants of the BRCA2 gene were studied in 149 study participants from the same cohort. There were 55 familial and 54 sporadic breast cancer patients, 20 at-risk individuals and 20 healthy controls. Direct sequencing (exon 11) and sequencing of abnormal bands after screening with single-strand conformation polymorphism (remaining exons) were used to detect mutations and sequence variants. Twenty-three sequence variants were found in the BRCA2 gene. Two novel pathogenic frame-shift additions resulting in a premature stop codon (c.2403 insA/exon 11, c.2667 insT/exon 11) were identified. Possibly pathogenic two novel missense mutations (c.1191 A>C/exon 10, c.5695 A>C/exon 11) one novel intronic variant (IVS15-21 insTT), four novel silent mutations (c.969 C>T/exon 9, c.1353 C>T/exon 10, c.2766 A>C/exon 11 and c.7452 A>G/exon 14) and one novel missense mutation (c.971 C>G/exon 9) were observed. One previously reported possibly pathogenic intronic variant (IVS81 G>C) and several previously reported silent mutations, missense mutations, and one 5' UTR polymorphism were detected. Pathogenic and possibly pathogenic mutations were more frequent in the BRCA2 gene among Sri Lankan familial breast cancer patients when compared to our previous findings for the BRCA1 gene.

Introduction

Breast cancer is a complex, multifactorial disease with a strong interplay between genetic and environmental factors (1). Worldwide, it is the most common malignancy in women accounting for 23% of all cancers and the primary cause of death. It is the second most common cancer when both genders are considered together (2). At present, in Sri Lanka, breast cancer in women diagnosed at a median age of 50 years contributes to approximately 25% of all cancers (3). The age-standardized incidence rate (ASR) of breast cancer per 100,000 women significantly differs between developed and developing countries, and ASR for female breast cancer is 18.4 in Sri Lanka (3-5).

Although several risk factors including family history predispose to breast cancer, the most potent appear to be mutations in the breast cancer susceptibility genes BRCA1 (MIM 113705) and BRCA2 (MIM 600185) (6). Even though familial breast cancer accounts for only 5-10% of all breast cancers, individuals carrying mutations in one of these genes have a 40-80% chance of developing breast cancer (7). The lifetime risk of developing breast cancer by the age of 70 years is 46-87% for BRCA1 and 26-84% for BRCA2 mutation carriers (8-10). The BRCA1 gene located on the long arm of chromosome 17 (17q21) consists of 24 exons coding for 1863 amino acids (11). The BRCA2 gene located on chromosome 13 (13q12.3) consists of 27 exons coding for 3418 amino acids (12). Both genes apparently function as tumour-suppressor genes and play a pivotal role in the control of homologous recombination and double-strand break repair in response to DNA damage (13-15).

We recently reported BRCA1 mutations in a cohort of Sri Lankan breast cancer patients (16) but BRCA2 germline mutations have not been previously characterized. Mutations in both genes together account for the majority of families with hereditary susceptibility to breast and ovarian cancer (17). Furthermore, mutations in the central portion of the BRCA2 gene [ovarian cancer cluster region (OCCR)] are reported to be associated with a significantly higher ratio of cases of ovarian:breast cancer in female carriers than the mutations in the 5' or 3' region (18). Mutations in the BRCA2 gene in men lead to an increased risk of cancers in the breast, prostate and pancreas (19).
De Silva et al.: BRCA2 Mutations in Sri Lankan Breast Cancer Patients

1164

BRCA1- and BRCA2-associated risks of developing cancer differ in geographical and historically defined groups. Ethnic group-specific mutations showing a high frequency of occurrence are referred to as founder mutations. Identification of a founder mutation is a vital step towards the improvement of genetic screening and counselling. It also facilitates more specific approaches to molecular testing (7,20). In the present study, 109 breast cancer patients, 20 at-risk individuals and 20 healthy controls were screened for BRCA2 mutations. Here, we report novel and previously reported pathogenic and possibly pathogenic mutations, intronic variants and common polymorphisms observed.

Materials and methods

Study participants. A total of 109 patients (n=55 with a family history of breast cancer and n=54 sporadic breast cancer), 20 at-risk individuals and 20 healthy controls without a personal or family history of any cancer were studied. They were study participants in whom we previously investigated BRCA1 mutations, and their characteristics have been previously described (16). The number of patients studied in the present study was slightly lower than that in the BRCA1 study. At-risk individuals were limited to members of a family with a history of breast and other cancers where one breast cancer patient and two unaffected family members carry a deleterious BRCA1 mutation but included an additional study participant than in the BRCA1 study. Characteristics of the study participants are summarised in Table I. Mean age at diagnosis was 47.76±9.55 and 47.60±10.49 years for familial and sporadic breast cancer patients, respectively. Fourteen familial and 10 sporadic breast cancer patients were diagnosed below 40 years of age. Among the familial cases 34, 17 and 3 patients had one, two and three affected family members, respectively. One patient had 4 affected family members. The majority of the patients and controls and all at-risk individuals were ethnically Sinhalese. There were no descendents of Europeans. Ethical approval from the Institution Review Board and written informed consent from the study participants were obtained prior to the study. Socio-demographic and clinical data were obtained from the study participants, and cancer diagnoses were confirmed by reviewing medical reports and pathology reports.

Samples. Genomic DNA was extracted using the protocol described by Miller et al (21) from aliquots of peripheral blood samples that had been stored at -20°C.

Prime design and PCR conditions. Nine sets of overlapping primers were designed for the exon 11 coding region and adjacent intronic region of BRCA2 using the website ‘Primer3: WWW primer tool’ (22). Specific primers for other exons of the BRCA2 gene for PCR amplification were selected from the BIC primer database.

Polymerase chain reaction (PCR) amplification was performed using each of the 40 primer pairs in a 25-µl volume containing 100 ng genomic DNA, 1.0-3.5 mmol/l MgCl2, 1X PCR buffer [10 mM Tris-HCl (pH 8.3) and 50 mM KCl], 2.5 mmol/l dNTPs (Promega, Madison, WI, USA), 5 pmols of each primer and 0.5 units of Taq polymerases (Promega). The PCR reaction was carried out for 33 cycles, and the thermal regime consisted of an initial denaturation at 94°C for 7 min, subsequent denaturation at 94°C for 1 min, annealing at the
Table II. Clearly pathogenic and possibly pathogenic BRCA2 mutations identified.

<table>
<thead>
<tr>
<th>E/I</th>
<th>NT</th>
<th>Base change</th>
<th>Codon</th>
<th>AA change</th>
<th>Designation</th>
<th>Variation type</th>
<th>BIC entry</th>
<th>Cases (%)</th>
<th>Pathogenic</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-8</td>
<td>910-1</td>
<td>G&gt;C</td>
<td>Non-coding</td>
<td>-</td>
<td>IVS8-1 G&gt;C</td>
<td>IVS</td>
<td>Yes</td>
<td>1 (0.78)</td>
<td>Clearly</td>
</tr>
<tr>
<td>10</td>
<td>1191</td>
<td>A&gt;C</td>
<td>321</td>
<td>Lys&gt;Asn</td>
<td>1191 A&gt;C</td>
<td>M-UV</td>
<td>No</td>
<td>4 (3.1)</td>
<td>Possibly</td>
</tr>
<tr>
<td>11*</td>
<td>2403 insA</td>
<td>726</td>
<td>Val&gt;Ser</td>
<td>2403 insA</td>
<td>F</td>
<td>No</td>
<td>4 (4.2)</td>
<td>Clearly</td>
<td></td>
</tr>
<tr>
<td>11*</td>
<td>2667 insT</td>
<td>813</td>
<td>Pro&gt;Ser</td>
<td>2667 insT</td>
<td>F</td>
<td>No</td>
<td>1 (1.05)</td>
<td>Clearly</td>
<td></td>
</tr>
<tr>
<td>11*</td>
<td>5695 A&gt;C</td>
<td>1823</td>
<td>Lys&gt;Gln</td>
<td>5695 A&gt;C</td>
<td>M-UV</td>
<td>No</td>
<td>6 (6.3)</td>
<td>Possibly</td>
<td></td>
</tr>
</tbody>
</table>

aExon 11 analysis was carried out only in 95 study participants (55 familial cases, 20 at risk individuals and 20 controls). E/I, exon/intron; F, frame-shift; IVS, intervening sequence/intron; M, missense alteration; UV, unclassified variants.

Results

This is the first report on BRCA2 mutations and polymorphisms in Sri Lankan breast cancer patients in whom BRCA1 mutations and sequence variants have been characterized recently (16). A total of 149 including 109 patients were studied, and twenty-three sequence variants were identified.

Clearly and possibly pathogenic mutations are shown in Table II. Two novel frame-shift mutations, c.2403 insA and c.2667 insT in exon 11, and two novel possibly pathogenic mutations, c.1191 A>C in exon 10 and c.5695 A>C in exon 11, and previously reported possibly pathogenic intronic variant, IVS8-1 G>C in intron 8, were detected. Sequence variants with unknown significance and polymorphisms are shown in Table III. Twelve previously reported polymorphisms in the exon 2 untranslated region (5’UTR) and in exon 10, 11 and 14 were identified (Table III). Six novel polymorphisms in exons 9, 10, 11, 14 and IVS15-21 insT in intron 15 were observed.

c.2403 insA in exon 11 (codon 726), a novel frame shift insertion, created a stop codon at exon 750 of the BRCA2 protein in four unrelated patients with a family history of breast cancer. All four of them were Sinhalese. Three of them, diagnosed with breast cancer at an early age (35, 38, 47 years) had one affected second degree relative each. The fourth patient diagnosed at the age of 51 years is unmarried and has a sister affected with breast cancer. Recurrence of the disease after 10 years of initial diagnosis was reported in one. Mutation c.2667 insT in exon 11 which is also novel created a stop codon at exon 825 in the BRCA2 protein. It was found in one patient diagnosed with breast cancer at 53 years of age having(137,969),(787,995)
a novel possibly pathogenic missense mutation, c.1191 A>C in exon 10. The same mutation was also found in 2 other at-risk individuals from the F-01 family (III.02, III.13) and in another familial breast cancer patient from a different family diagnosed at the age of 49 years and having one first and one second degree relative affected.

A previously reported possibly pathogenic intronic variant, IVS8-1 G>C in intron 8, was detected in one patient with breast cancer and ovarian cancer both occurring at the age of 46 years. She also has co-existing novel silent (c.969 C>T) and missense (c.971 C>G) mutations in exon 9. This patient has two second degree relatives affected with breast cancer.

Novel unclassified variant IVS15-21 insTT in intron 15 was found in one patient diagnosed at 43 years of age whose mother also had breast cancer. Analysis of the IVS15-21 insTT intronic variant using Human Splicing Finder version 2.4
Table IV. Mutations and polymorphisms in the *BRCA2* gene among the F-01 family members.

<table>
<thead>
<tr>
<th>Individuals</th>
<th>BRCA2 mutations and polymorphisms*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>II.4</td>
</tr>
<tr>
<td>2</td>
<td>II.13</td>
</tr>
<tr>
<td>3</td>
<td>III.02</td>
</tr>
<tr>
<td>4</td>
<td>III.03</td>
</tr>
<tr>
<td>5</td>
<td>III.06</td>
</tr>
<tr>
<td>6</td>
<td>III.07</td>
</tr>
<tr>
<td>7</td>
<td>III.09</td>
</tr>
<tr>
<td>8</td>
<td>III.11</td>
</tr>
<tr>
<td>9*</td>
<td>III.12</td>
</tr>
<tr>
<td>10</td>
<td>III.13</td>
</tr>
<tr>
<td>11</td>
<td>III.14</td>
</tr>
<tr>
<td>12*</td>
<td>III.16</td>
</tr>
<tr>
<td>13*</td>
<td>III.19</td>
</tr>
<tr>
<td>14</td>
<td>III.22</td>
</tr>
<tr>
<td>15</td>
<td>IV.01</td>
</tr>
<tr>
<td>16</td>
<td>IV.02</td>
</tr>
<tr>
<td>17</td>
<td>IV.03</td>
</tr>
<tr>
<td>18</td>
<td>IV.05</td>
</tr>
<tr>
<td>19</td>
<td>IV.07</td>
</tr>
<tr>
<td>20</td>
<td>IV.08</td>
</tr>
<tr>
<td>21</td>
<td>IV.09</td>
</tr>
</tbody>
</table>

*aUpper number indicates the nucleotide position and the lower number indicates the exon. *BRCA1* mutation carriers (5404delG in exon 21). Patient no. 12 (III.16) is a breast cancer patient and no. 5 (III.06) has benign breast disease.*
showed that the acceptor motif of the exon 16 (at -12 region) is located several bases away (downstream) from the detected variant (24).

We found four previously reported (c.1093 A>C, c.1342 A>C (p.N372H), c.1352 C>T, c.1593 A>G) and one novel (c.1353 C>T) polymorphism in exon 10. Missense mutation c.1093 A>C was identified in six familial and three sporadic breast cancer patients, 3 at-risk individuals but in none of the healthy controls. c.1342 A>C (p.N372H) was the most prevalent polymorphism, and the prevalence was significantly higher among familial breast cancer patients and at-risk individuals (80%) than among sporadic breast cancer patients (24%) and healthy controls (25%). Missense mutation c.1352 C>T was detected in four familial breast cancer patients and 1 at-risk individual, silent mutation c.1593 A>G in one familial breast cancer patient and 4 at-risk individuals and novel silent mutation c.1353 C>T in one familial breast cancer patient and 2 at-risk individuals. These three mutations were not found in sporadic breast cancer patients or healthy controls. All five polymorphisms in exon 10 co-existed in one at-risk individual from the F-01 family (III.02).

In addition to the clearly and possibly pathogenic mutations, we detected seven other sequence variants in exon 11. These were three reported silent mutations (c.2457 T>C in one at-risk individual, c.3624 A>C in 6 at-risk individuals and one healthy control and c.4035 T>C in 1 at-risk individual), one novel silent mutation (c.2766 A>C in 1 at-risk individual), a reported missense mutation (c.3538 A>C in one familial breast cancer patient) and two reported common polymorphisms (c.4791 A>G and c.6741 G>C). Prevalence of the two common polymorphisms did not significantly differ between familial breast cancer patients, at-risk individuals and healthy controls and these were not studied in sporadic breast cancer patients.

We found the previously reported polymorphism c.203 G>A in exon 2 in >60% of the familial and sporadic breast cancer patients and at-risk individuals but at a lower prevalence (16.5%) among the healthy controls. A novel common polymorphism c.7452 A>G in exon 14 was also found in the familial and sporadic breast cancer patients and at-risk individuals but not in any healthy controls. One at-risk individual also carried the reported silent mutation c.7470 A>G in exon 14 in addition to this polymorphism. The most common four polymorphisms, c.203 G>A in exon 2, c.1342 A>C in exon 10, and c.4791 A>G and c.6741 G>C in exon 11, identified in the present study co-existed in several familial patients, at-risk individuals and healthy controls.

Discussion

After screening a predominantly Sinhalese cohort of familial and sporadic breast cancer patients, at-risk individuals from a family carrying a deleterious BRCA1 mutation and healthy controls, we identified 23 sequence variants in the BRCA2 gene. Two novel pathogenic frame-shift mutations resulting in a premature stop codon in exon 11 and two novel possibly pathogenic mutations one each in exon 10 and 11 and a previously reported pathogenic variant in intron 8 were detected. One novel intronic variant in intron 15 and five novel polymorphisms were observed, two in exon 9 and one each in exons 10, 11 and 14. Twelve previously reported polymorphisms were identified, one in the exon 2 untranslated region (5’UTR), four in exon 10, six in exon 11 and one in exon 14.

The two clearly pathogenic mutations identified in the present study (c.2403 insA and c.2667 insT) are frame-shift insertions in exon 11 leading to a premature stop codon and thus resulting in a truncated protein. Of these, the c.2403 insA occurred in four unrelated familial breast cancer patients of Sinhalese ethnicity indicating that it is likely be a common mutation among familial breast cancer patients in this ethnic group. The number of study participants from other ethnic groups was small, thus one cannot exclude the presence of this mutation in other ethnic groups in Sri Lanka. The other deleterious mutation was found only in one patient.

Mutation c.5695 A>G found in several members of the F-01 family is located in the sixth BRCA repeat (BRC6 repeat) out of the eight BRC repeats encoded by exon 11. The BRC repeats mediate the binding of DNA repair protein Rad51 (25). DNA recombinase RAD51 and BRCA2 protein complex is crucial for the repair of double-strand DNA breaks (26). As this mutation alters lysine (basic polar amino acid) at codon 1823 to glutamine (neutral polar amino acid) it may change conformation of the protein rendering pathogenicity. One at-risk individual found to have this mutation was affected with salivary cancer, diagnosed at the age of 13 years and another was diagnosed with a benign breast tumour at the age of 32 years. The remaining four members carrying this mutation are, at present, free from benign or malignant breast disease or any other cancer despite one of them also carrying a deleterious BRCA1 mutation.

Novel missense mutation c.1191 A>C in exon 10 found in one familial breast cancer patient and 3 at-risk individuals in the present study, alters amino acid lysine (basic polar amino acid) to asparagine (neutral polar amino acid) at codon 321. This too can be functionally significant, as it may affect the conformation of the protein.

Nearly 23 and 6.5% of unclassified variants in BRCA1 and BRCA2, respectively, are located in intronic sequences but only few studies have been carried out to identify whether these variants affecting RNA splicing are involved in the pathogenicity of breast cancer (27). According to the BIC database, the intronic variant IVS8–1 G>C located at the splice-site of the intron is clinically important (28). To date, none of the Asian countries have reported this mutation although this has been reported in Western Europe. In exon 9, novel missense mutation c.971 C>G alters amino acid alanine (nonpolar aliphatic) to glycine (nonpolar aliphatic) at codon 247. This co-existed with the novel silent mutation c.969 C>T in the same patient, and both these sequence variants are unlikely to be of clinical importance. However, the patient who carries these mutations has a previously reported possibly pathogenic intronic variant, IVS8–1 G>C in intron 8.

Only ten intronic variations have been identified in intron 15 and none of the Asian countries have reported variants in this intron (28). In the present study, we found a novel unclassified variant, IVS15–2 1insTT in intron 15, in one familial breast cancer patient. However, results from the bioinformatic analysis using Human Splicing Finder version 2.4 did not indicate this variant to be pathogenic (24).

One novel and four previously reported polymorphisms were found in exon 10. Missense polymorphism c.1342 A>C
(BRCA2 p.N372H) occurred more frequently in the familial breast cancer patients and at-risk individuals from family F-01 when compared to the sporadic breast cancer patients and healthy controls suggesting a predisposition to familial breast cancer in its presence. This polymorphism results in non-conservative amino acid substitution [asparagine (N) to histidine (H)], hence may affect the structure and function of the BRCA2 protein. N372H locates within a region of BRCA2 (residues 290-453) that has been shown to interact with a transcriptional co-activator protein, P/CAF, which possesses histone acetyltransferase activity (29). The HH genotype of the N372H polymorphism in the BRCA2 gene was reported to be associated with a 1.3-fold increased risk of breast cancer in a combined analysis of British, German and Finnish women (30) and in Australian women (31) but others have failed to find a significant effect in older Caucasian women (32). The N372H polymorphism had an allele frequency of 0.45 in the present study, which was higher than the average frequency of 0.26 reported in British, German and Finnish populations (30). This polymorphism was also reported in a Malaysian population among Malay, Chinese and Indian ethnic groups (33). A more recent meta-analysis failed to show an effect of this polymorphism on breast cancer even when a subgroup analysis by ethnicity was carried out but showed an effect in population-based studies (34). These authors have suggested the BRCA2 p.N372H allele as a low-penetrant risk factor for developing breast cancer.

Missense mutation c.1093 A>C found in six familial breast cancer patients with a strong family history of breast cancer and 3 at-risk individuals has also been reported in studies in Denmark and two Asian countries, Japan (35) and Malaysia (33). Two patients had mothers, three patients had maternal aunts and two patients had maternal grandparents affected with breast cancer. Apart from that, there were two paternal relations of these patients affected with breast cancer. The c.1593 A>G polymorphism detected in one familial breast cancer patient and 4 at-risk individuals has been reported from Western countries (28) and from Asia (33,35,36). Co-existence of all five polymorphisms has not been reported previously, but the presence of c.203 G>A in exon 2, c.1342 A>C in exon 10 and c.3624 A>G in exon 11 has been reported in the Spanish population (28).

The prevalence of clearly pathogenic BRCA2 mutations was 11% (6/55) and, clearly and possibly pathogenic BRCA2 mutations was 12.73% (7/55) among the familial breast cancer patients. Thus when compared to our previous observation of a prevalence of 6.25% for BRCA1 mutations (16), BRCA2 mutations appear to be more frequent in Sri Lankan familial breast cancer patients.

In Sri Lanka, approximately 19% of female breast cancers are diagnosed in women below 50 years of age suggesting a significant genetic susceptibility. However, genetic screening programmes are not in place due to the lack of data on mutations associated with breast cancer for the Sri Lankan population and high cost. We identified two pathogenic and three possibly pathogenic mutations in the BRCA2 gene in familial breast cancer. Of these, c.2403 insA in exon 11, the pathogenic mutation which occurred in 4 out of 51 unrelated Sinhalese patients, is likely to be useful in screening programmes.

Acknowledgements

We thank the director and staff of the National Cancer Institute, Maharagama, Sri Lanka for their cooperation, Dr Nalinda Silva for assistance with sample collection, Dr Mohamed H. Ziard for assistance with sample collection from the F-01 family. This study was supported by the Sida/Secretariat for Research Cooperation Grant for Molecular Biology and Biotechnology awarded to E.H.K. and K.H.T. and constituted partly to the PhD programme of S.deS.

References